Effectiveness of chromium in atypical depression: a placebo-controlled trial

1994

Anderson, 1998, Chromium, glucose intolerance and diabetes, J Am Coll Nutrition, 17, 548, 10.1080/07315724.1998.10718802

Anderson, 1987, Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia, Metabolism, 36, 351, 10.1016/0026-0495(87)90206-X

Attenburrow, 2002, Chromium treatment decreases the sensitivity of 5HT2A receptors, Psychopharmacology, 159, 432, 10.1007/s00213-001-0960-7

Barnett, 2001, Tolerability of fluoxetine in posttraumatic stress disorder, Prog Neuropsychopharmacol Biol Psychiatry, 26, 363, 10.1016/S0278-5846(01)00282-2

Cohen, 1988

Connor, 2001, Adverse effect profile of kava, CNS Spectrums, 6, 848, 10.1017/S109285290000167X

Davidson, 1988, An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology, Arch Gen Psychiatry, 45, 120, 10.1001/archpsyc.1988.01800260024003

Davidson, 1982, Atypical depression, Arch Gen Psychiatry, 39, 527, 10.1001/archpsyc.1982.04290050015005

Davidson, 1989, Classification of depression by grade of membership, Psychol Med, 19, 987, 10.1017/S0033291700005717

Davis, 1997, Chromium oligopeptide activates insulin receptor kinase activity, Biochemistry, 36, 4382, 10.1021/bi963154t

Derogatis, 1973, SCL-90, Psychopharmacol Bull, 9, 13

Guy, 1976

Hamilton, 1982, The effect of treatment on the melancholias (depressions), Br J Psychiatry, 140, 223, 10.1192/bjp.140.3.223

Horacek, 1999, The relationship between central serotonergic activity and insulin sensitivity in healthy volunteers, Psychoneuroendocrinology, 24, 785, 10.1016/S0306-4530(99)00026-8

Jarrett, 1999, Treatment of atypical depression with cognitive therapy or phenelzine, Arch Gen Psychiatry, 56, 431, 10.1001/archpsyc.56.5.431

McCarthy, 1994, Enhancing central and peripheral insulin activity as a strategy for treatment of endogenous depression—an adjuvant role for chromium picolinate, Med Hypotheses, 43, 247, 10.1016/0306-9877(94)90075-2

McGrath, 1994, Gepirone treatment of atypical depression, J Clin Psychopharmcol, 14, 347

McLeod, 1999, Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in five patients, J Clin Psychiatry, 60, 237, 10.4088/JCP.v60n0406

McLeod, 2000, Chromium treatment of depression, Int J Neuropsychopharmacol, 3, 311, 10.1017/S146114570000208X

Pande, 1996, Fluoxetine versus phenelzine in atypical depression, Biol Psychiatry, 40, 1017, 10.1016/0006-3223(95)00628-1

Paykel, 1972, Classification of depressed patients, Br J Psychiatry, 118, 275, 10.1192/bjp.118.544.275

Paykel, 1973, Amitriptyline, weight gain and carbohydrate craving, Br J Psychiatry, 123, 501, 10.1192/bjp.123.5.501

Posternak, 2002, Partial validation of the atypical features subtype of major depressive disorder, Arch Gen Psychiatry, 59, 70, 10.1001/archpsyc.59.1.70

Quitkin, 1993, Columbia atypical depres-sion, Br J Psychiatry, 163, 30, 10.1192/S0007125000292465

Sheehan, 1998, The Mini-International Neuropsychiatric Interview (MINI), J Clin Psychiatry, 59, 22

Stewart, 1993, Atypical depression. A valid clinical entity?, Psychiatric Clin North Am, 16, 479, 10.1016/S0193-953X(18)30161-8

Thase, 1996, A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia, Arch Gen Psychiatry, 53, 777, 10.1001/archpsyc.1996.01830090023004